Here's what I got for a reply from the CFO:
Other than the melt down of the world markets and loss of investor confidence generally, there are no company-specific factors that can be attributed to the recent fall in the Company's share price. The Phase 2 extension trial and Phase III pivotal trial are continuing as planned and there have been no Company announcements to affect the share price over the last week or so.